Research

Upcoming Projects

  • Project RIDE — Rapid Initiation of Drug Treatment Engagement — Spring 2019

  • HVTN 115B — A Phase I clinical trial to evaluate the safety and immunogenicity of EnvSeq-1 and CH505.M5 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adult participants. — expected to begin screening late summer 2019

  • HVTN 132  —  A phase 1 clinical trial to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of GEO-D02 DNA and MVA/HIV62 with and without B.63521Δ11gp120mutC and IHV01 gp120 Env proteins in healthy, HIV-uninfected adult participants.  — expected to begin screening late summer 2019

Close

Ongoing Projects Closed to Enrollment

  • HPTN 083 — A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men.
  • HVTN 704/HPTN 085 AMP (Antibody Mediated Prevention) Study — A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men.
  • HVTN 124   — A Phase I clinical trial to evaluate the safety and immunogenicity of Polyvalent env (A, B, C, E)/gag (C) DNA and gp 120 (A,B,C,E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as either a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1 uninfected adult participants.
  • HVTN 120   — A phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants.
  • HVTN 122  — A Phase 1 double-blind, randomized clinical trial clinical trial to evaluate the safety and immunogenicity of MHRP recombinant trimeric gp145 Env in healthy, HIV-1 uninfected adult participants.
  • HVTN 117 — The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C glycoprotein (gp)140 plus adjuvant. Immune responses of the different vaccine schedules will be assessed.
  • HVTN 116 — A phase 1 clinical trial to evaluate the safety, pharmacokinetics, and anti-viral activity of VRC HIVMAB060 00 AB (VRC01) and VRC HIVMAB080 00 AB (VRC01LS) in the serum and mucosa of healthy, HIV-uninfected adult participants
  • HVTN 118 — The primary purpose of this study is to assess safety/tolerability of the different vaccine regimens and to assess envelope (Env)-binding antibody (Ab) responses of the 2 different vaccine regimens.
  • HVTN 112  — A phase 1 trial to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of HIV-1 nef/tat/vif, env pDNA vaccine delivered intramuscularly with electroporation and HIV-1 rVSV envC vaccine in healthy HIV-uninfected adult participants.
  • HVTN 110  — A Phase 1 clinical trial to evaluate the safety and immunogenicity of orally-administered replication-competent Adenovirus type-4 HIV vaccine regimens in healthy, HIV-uninfected adult participants.

Close

Completed Projects

  • HVTN 104
  • GSK PrEP ECLAIR
  • HVTN 105
  • HVTN 092
  • HVTN 505
  • HVTN 070
  • HVTN 080
  • HVTN 085
  • HVTN 087
  • HVTN 090
  • HVTN 092
  • HPTN 037
  • HVTN 906

Close

HIV Treatment & AIDS Prevention Research

PATH

e-PATH

Close

 

 

 


Back to Top